Board of Directors

Neil FlanzraichExecutive Chairman of Cantex Pharmaceuticals, Inc.
Former Vice Chairman and President of IVAX Corporation

Mr. Flanzraich brings to Alzheon more than 30 years of executive leadership, operations and legal experience with pharmaceutical and life sciences companies.  Mr. Flanzraich was an early investor in Alzheon and served in the role of Chief Business Officer of Alzheon as a consultant to the company from February to May 2018.

Mr. Flanzraich is the Executive Chairman of Cantex Pharmaceuticals, Inc., a privately-owned biotech company, which is developing drugs for cancer.  Previously, he was Cantex’s Chief Executive Officer.  Mr. Flanzraich served as Vice Chairman and President of IVAX Corporation, an international pharmaceutical company, for over seven years, prior to its sale in 2006 to TEVA Pharmaceutical Industries, Ltd. for an enterprise value of $10 billion.  Prior to his tenure at IVAX, Mr. Flanzraich served as Chairman of the Life Sciences Legal Practice Group of Heller Ehrman LLP, a law firm.  Previously Mr. Flanzraich worked at Syntex Corporation, an international pharmaceutical company, where, as the Senior Vice President, and a member of both the Corporate Operating and Corporate Executive Committees, he made major contributions to the value of the company, which was acquired by Roche in 1994 for $5.3 billion.

Mr. Flanzraich was an early investor and member of the board of directors of Chipotle Mexican Grill, Inc. (NYSE: CMG), and is currently its lead independent director.  Mr. Flanzraich was the lead independent director of Equity One, Inc. (NYSE: EQY), prior to its acquisition by Regency Centers Corporation in 2017.  He was an independent director of Continucare Corporation (NYSE: CNU), a company with primary care centers, from 2002 to its sale in 2011.  Mr. Flanzraich received an AB from Harvard College and a JD from Harvard Law School.

We believe that Mr. Neil Flanzraich is qualified to serve on our board of directors because of his business expertise and extensive experience in the pharmaceutical and biotechnology industries.

Franz Hefti AlzheonChief Operating Officer, Proclara Biosciences

Franz Hefti, Ph.D. has served on our board of directors since April 2014. Dr. Hefti has also served as the Chief Operating Officer of Proclara Biosciences, Inc., a biotechnology company, since June 2015. Before that, Dr. Hefti served in senior managerial position at various biotechnology and pharmaceutical companies, including from November 2011 to January 2015 as President and Chief Executive Officer of Acumen Pharmaceuticals, Inc., an AD diagnostic and therapy company, from January 2007 to December 2010 as Chief Scientific Officer of Avid Radiopharmaceuticals, Inc., a pharmaceutical company, from February 2003 to June 2006 as Executive Vice President of Rinat Neuroscience Corp., a biotechnology company, from September 1995 to December 2002 as Senior Vice President of Neuroscience Research at Merck & Co., a pharmaceutical company, and from January 1992 to August 1995 as Director of Neuroscience Research at Genentech Inc. a biotechnology company.

We believe that Dr. Hefti is qualified to serve on our board of directors because of his extensive experience in the pharmaceutical and biotechnology industries, particularly in AD.

David Nikodem AlzheonManaging Director and Partner, Beacon Pointe Wealth Advisors

Jordan Heller CFA, CFP®, CPA is a Managing Director and Partner of Beacon Pointe Wealth Advisors having founded Heller Wealth Management prior to merging it with Beacon Pointe. Prior to Beacon Pointe, Mr. Heller was a partner of The Schonbraun McCann Group (SMG), currently FTI Consulting, as well as managing partner of SMG’s wealth management subsidiary. Prior to joining the Schonbraun McCann Group, Mr. Heller spent four years at American Economic Planning Group (AEPG) in a similar capacity. Prior to entering the wealth management industry in 2000, Jordan spent 15 years on Wall Street heading the Real Estate and Real Estate Finance Securities Research group at some of the country’s leading investment houses, including Merrill Lynch, Salomon Brothers and CIBC. During this time, Jordan played a leading role in the rebirth of the modern-day REIT industry. He began his career in public accounting, joining Price Waterhouse in 1982, and moving to Wall Street in 1985. Jordan has extensive investment banking, advisory, and research experience.

Jordan serves on the Board of Directors of Bed Bath and Beyond and served on the board of Equity One until it’s sale to Regency Centers in 2017. He is a member of the Board of Trustees of the New York College of Podiatric Medicine, is a member of the Investment Management Consultants Association, Association for Investment Management and Research and the New York Society of Security Analysts. Jordan obtained his undergraduate degree from Bentley University in Waltham, MA, with a B.S. in Accountancy.

We believe that Mr. Jordan Heller is qualified to serve on our board of directors because of his business expertise and extensive investment experience.

David Nikodem AlzheonAlly Bridge Group

David P. Nikodem, Ph.D. was nominated to our board of directors by ABG II-Alzheon Limited, one of our shareholders, and has been a member of our board of directors since December 2014. Dr. Nikodem has also served as a senior representative of Ally Bridge Group, or ABG, and serves on the boards of several of ABG’s U.S.-based biopharmaceutical companies. From December 2010 to September 2013, Dr. Nikodem served as Portfolio Manager at Exane Asset Management, an asset management company, where he managed a global healthcare fund.

Dr. Nikodem received his Ph.D. in molecular biology from Georgetown University.

We believe that Dr. Nikodem is qualified to serve on our board of directors because of his investment experience and knowledge of the pharmaceutical and biotechnology industries.

Martin Tolar AlzheonFounder, President & Chief Executive Officer, Alzheon, Inc.

Prior to founding Alzheon in June 2013, Dr. Tolar has held executive positions in life sciences companies, where he has successfully established and grown new companies, business areas and product opportunities. Dr. Tolar served as President & CEO of Knome, Inc., where he led the development of human genome interpretation systems and services for academic, pharmaceutical and clinical clients, as President & CEO at NormOxys, Inc., where he built the business for novel cancer therapeutics, and as Chief Scientific Officer and Chief Business Officer at CoMentis, Inc., where he developed the first clinical-stage beta secretase inhibitor platform for Alzheimer’s disease and negotiated a collaboration with a potential value of $1.1 billion with Astellas Pharma in 2008. Dr. Tolar held a variety of clinical development and business leadership positions at Pfizer, where he was instrumental in a wide range of business transactions, including acquisition of Rinat Neuroscience for $500 million in 2006, and directed programs through all stages of clinical development and FDA approval including NDA filings.

During his academic career, Dr. Tolar served as an Assistant Professor in the Department of Neurology at Yale University School of Medicine, where he focused on movement disorders. Dr. Tolar trained in Neurology at the Boston Medical Center, received a Ph.D. in Neuroscience for his work on the role of apolipoprotein E in Alzheimer’s disease, and published many scientific publications in the area of neuroscience and neurodegenerative disorders. Dr. Tolar received his M.D. from Charles University in Prague, where as a medical student he helped organize and lead the Velvet Revolution that toppled the communist regime in the former Czechoslovakia in November 1989.

Dr. Tolar serves on business and scientific boards including the Alzheimer’s Drug Discovery Foundation, the Alzheimer Foundation and Advance Healthcare Management Institute.

Dr. Tolar was recognized as one of the Top 100 Most Influential People in the world of drug development and manufacture by The Medicine Maker Magazine’s Power Lists for 2016, 2017 and 2018.

We believe that Dr. Tolar is qualified to serve on our board of directors because of his scientific expertise and extensive experience in the pharmaceutical and biotechnology industries.